Home › Trial NCT06751134
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
- Trial IDNCT06751134
- StatusRecruiting
- PhasePhase 1
- Study typeInterventional
- SponsorNanjing Children's Hospital
- Enrollment12
- Start date2024-12-28
- ConditionsNeuroblastoma, Recurrent, Refractory
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.